Sep 6, 2025, 14:04
Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
Dr. Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared an insightful post on X:
“ASH 2018 VTE Prophylaxis in Pregnancy
Prior VTE
- Unprovoked / hormone-related → Antepartum: Yes, Postpartum: Yes
- Provoked (transient risk only) → Antepartum: No, Postpartum: Yes
Thrombophilia
Heterozygous FVL / Prothrombin G20210A
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Protein C deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Protein S deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Compound heterozygosity
- No FHx → Antepartum: No, Postpartum: Yes
- +FHx → Antepartum: Yes, Postpartum: Yes
Homozygous FVL
- No FHx → Antepartum: No, Postpartum: Yes
- +FHx → Antepartum: Yes, Postpartum: Yes
Homozgous Prothrombin
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Panel unable to recommend, Postpartum: Yes
Antithrombin deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Other risks
- No or 1 risk factor → Antepartum: No, Postpartum: Yes
- Assisted reproduction →
-Without ovarian hyperstimulation / high-risk → Antepartum: No
-With OHSS or high-risk thrombophilia → Antepartum: Yes, Postpartum: Yes
Pearls for exams
- Postpartum period = highest risk → most recommendations support prophylaxis here
- Antepartum prophylaxis reserved for high-risk thrombophilia with FHx or prior unprovoked/hormonal VTE
- LMWH = preferred agent
Reference: ASH-SAP 9th Ed, Table 3-2”
More series on VTE featured in Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!